HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

J. Biol. Chem., Vol. 280, Issue 27, 25506-25511, July 8, 2005

This Article Abstract Full Text (PDF) All Versions of this Article: 280/27/25506    most recent M504815200v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Devlin, A. M. Articles by Lentz, S. R. Search for Related Content PubMed PubMed Citation Articles by Devlin, A. M. Articles by Lentz, S. R. Social Bookmarking                      What's this?

Tissue-specific Changes in H19 Methylation and Expression in Mice with Hyperhomocysteinemia^*

Angela M. Devlin, Teodoro Bottiglieri¶, Frederick E. Domann||, and Steven R. Lentz**

From the Departments of Internal Medicine and^|| Radiation Biology, University of Iowa Carver College of Medicine, Iowa City, Iowa 52242, the^** Veterans Affairs Medical Center, Iowa City, Iowa 52246, and the ^¶Baylor Institute of Metabolic Disease, Dallas, Texas 75226

Received for publication, May 2, 2005 , and in revised form, May 17, 2005.

	ABSTRACT

TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 
Expression of the imprinted genes H19 and insulin-like growth factor 2 (Igf2), which lie in close proximity on mouse chromosome 7, is regulated by methylation of a differentially methylated domain (DMD) located 5' to H19. Biallelic expression of H19 has been observed in renal disease patients with hyperhomocysteinemia, a cardiovascular disease risk factor. The present study determined whether hyperhomocysteinemia produces decreased tissue methylation capacity, hypomethylation of the H19 DMD, and altered expression of H19 and Igf2 in adult mice. Mice heterozygous for disruption of the gene for cystathionine--synthase (Cbs+/–) and C57BL/6 (Cbs+/+) mice were fed a hyperhomocysteinemic or control diet, respectively, from weaning until 9–12 months of age. Higher plasma total homocysteine (p < 0.001) was found in hyperhomocysteinemic mice than in control mice (95 ± 12 versus 5.0 ± 0.3 µmol/liter). Hyperhomocysteinemia was accompanied by higher levels of S-adenosylhomocysteine (p < 0.05) and lower S-adenosylmethionine/S-adenosylhomocysteine ratios (p < 0.001) in liver and brain. The effect of hyperhomocysteinemia on H19 DMD methylation was tissue-specific. In liver, hyperhomocysteinemic mice had decreased H19 DMD methylation (p < 0.001). In brain, hyperhomocysteinemia was accompanied by increased H19 DMD methylation (p < 0.001) and a decrease in the ratio of H19/Igf2 transcripts (p < 0.05). In aorta, hyperhomocysteinemia produced an increase in H19 DMD methylation (p < 0.001) and a 2.5-fold increase in expression of H19 transcripts (p < 0.05). Levels of H19 transcripts in aorta correlated positively with plasma total homocysteine concentration (p < 0.05, r = 0.620). We conclude that hyperhomocysteinemia produces tissue-specific changes in H19 DMD methylation and increased vascular expression of H19 in adult mice.

	INTRODUCTION

TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 
Methylation of DNA is an epigenetic process involved in genomic imprinting, X-chromosome inactivation, and gene expression in cancer (1). Recent evidence suggests that DNA methylation may play a role in the pathology of cardiovascular disease. Global DNA hypomethylation has been observed in advanced atherosclerotic lesions of humans, rabbits, and mice (2–4). Apolipoprotein E-deficient mice have been found to have aberrant DNA methylation patterns involving both hypo- and hypermethylation of DNA in aorta and peripheral blood mononuclear cells but not in liver and skeletal muscle (4). Alterations in DNA methylation profiles were detected prior to the appearance of atherosclerotic lesions, suggesting a pathogenic role for changes in DNA methylation in the progression of atherosclerosis (4). In some models of atherosclerosis, changes in DNA methylation of specific genes, such as extracellular superoxide dismutase (3) and estrogen receptor (5), have been observed.

Elevation of plasma total homocysteine (tHcy)¹ is a cardiovascular disease risk factor, the vascular pathology of which may involve altered DNA methylation (6). Homocysteine is metabolically linked to methylation reactions through the methionine cycle. Within the cycle, methionine is converted to S-adenosylmethionine (AdoMet), which serves as a methyl donor for numerous methyl acceptors, including DNA (7). S-Adenosylhomocysteine (AdoHcy) is produced as a byproduct of methyl donation, and homocysteine is formed through the (reversible) liberation of adenosine from AdoHcy. In human subjects with hyperhomocysteinemia, intracellular AdoHcy levels may increase, resulting in a lower AdoMet/AdoHcy ratio, diminished methylation capacity, and global DNA hypomethylation (8, 9). In mouse models of hyperhomocysteinemia produced by targeted disruption of the cystathionine -synthase (Cbs) or methylenetetrahydrofolate reductase (Mthfr) genes, decreased AdoMet/AdoHcy ratios and global DNA hypomethylation have been observed (10–12).

The imprinted gene H19 is located on mouse chromosome 7 in close proximity to the Igf2 gene, which encodes insulin-like growth factor 2 (IGF2). These two genes are reciprocally imprinted in both mice and humans, with H19 expressed from the maternal allele and Igf2 expressed from the paternal allele (13, 14). Paternal-specific methylation of an imprinting control region located 5' to H19 is a major regulator of imprinting (13). A differentially methylated domain (DMD) within the imprinting control region is thought to function as a boundary/insulator element (14–16). On the maternal allele, the H19 DMD is generally unmethylated, which allows binding of the zinc finger DNA-binding protein, CCCTC-binding factor (CTCF) (14, 15). CTCF is thought to allow distal enhancers to activate H19 transcription while blocking enhancer access to Igf2. On the paternal allele, the H19 DMD remains methylated, which prevents CTCF binding and enhancer activation of H19 transcription. Biallelic expression of H19 has been observed in peripheral blood mononuclear cells of human subjects with hyperhomocysteinemia and renal disease (17), which suggests that changes in cellular methylation capacity during hyperhomocysteinemia may be accompanied by hypomethylation of the H19 DMD and consequent loss of imprinting of H19. The vascular consequences of altered expression of H19 and Igf2 are unknown, but increased expression of H19 transcripts has been observed in a rat model of carotid artery injury (18) and in human atherosclerotic plaques (19), and there is evidence that IGF2 may promote atherosclerosis in mice (20).

The goal of the present study was to test the hypothesis that reduced methylation capacity in Cbs+/– mice with hyperhomocysteinemia is accompanied by hypomethylation of the H19 DMD and altered expression of H19 and Igf2. Cbs-deficient mice were chosen as an animal model for homocysteine-related vascular pathology because they are susceptible to diet-induced increases in plasma tHcy and have homocysteine-related endothelial dysfunction (11, 21, 22). Our findings demonstrate that hyperhomocysteinemic mice have tissue-specific alterations in methylation of the H19 DMD and in expression of H19 and Igf2. The relationship between changes in DMD methylation and expression of H19 and Igf2 was stronger in brain than in liver or aorta. Hyperhomocysteinemia produced a 2.5-fold increase in H19 expression in the aorta, which suggests a possible role for H19 in the vascular pathology of hyperhomocysteinemia.

	MATERIALS AND METHODS

TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 
Mice and Experimental Protocol—Mice heterozygous for targeted disruption of the Cbs gene (Cbs+/–) (23), on a C57BL/6 background, and their wild-type C57BL/6 littermates (Cbs+/+) were used in the study. Genotyping for the wild-type Cbs allele was conducted by PCR using the following primers: CbsI3, 5'-AAGAGCCCAGCAGAATGAACA-3', and P10, 5'-GGTCTGGAATTCACTATGTAGC-3'. Genotyping for the disrupted Cbs allele, Cbs^tm1Unc, was accomplished by PCR using the P10 primer and a primer corresponding to the neo cassette used in the targeted disruption (23). At weaning, Cbs+/– and Cbs+/+ mice were fed either a control diet (LM485, Harlan Teklad, Madison, WI) or a hyperhomocysteinemic (HH) diet (TD 00205, Harlan Teklad). The HH diet contained double the amount of methionine, minimal folic acid, and lower choline, pyridoxine, cobalamin, and riboflavin (Table I). The diets contained adequate levels of all nutrients except for folate in the HH diet (12). The HH diet also contained succinyl sulfathiazole to inhibit growth of intestinal bacteria, another source of folic acid. We have shown previously that Cbs+/– fed a control diet and Cbs+/+ mice fed an HH diet have only moderately elevated levels of plasma tHcy (11). We chose, therefore, to perform comparisons between Cbs+/+ mice fed the control diet and Cbs+/– mice fed the HH diet to maximize the difference in plasma tHcy between groups. After 9–12 months on the diets, mice were anesthetized with sodium pentobarbital (150 mg/kg intraperitoneally), and blood was collected by cardiac puncture. Samples of liver and brain were immediately deproteinized in ice-cold 0.4 mol/liter perchloric acid, homogenized, and centrifuged. The supernatant fraction was immediately frozen and stored at –80 °C for later AdoMet and AdoHcy analysis. Additional samples of liver and brain were flash-frozen and stored at –80 °C for later extraction of genomic DNA and RNA. The aortas were removed, flash-frozen, and stored at –80 °C for later extraction of genomic DNA and RNA. The protocol was approved by the University of Iowa and Veterans Affairs Animal Care and Use Committees.

View larger version (10K): [in this window] [in a new window]   FIG. 1. Plasma concentration of tHcy. Open bar, Cbs+/+ mice fed the control diet (n = 14); filled bar, Cbs+/– mice fed the HH diet (n = 15). Mice were fed the respective diets from weaning for 29-49 weeks. Values shown are mean ± S.E., *, p < 0.001, as determined by one-way analysis of variance.

Bisulfite Treatment—The protocol used was adapted from Frommer et al. (27). Genomic DNA was extracted from liver and brain using the DNeasy kit (Qiagen, Valencia, CA) and from aorta using TRIzol reagent (Invitrogen). Genomic DNA samples (1–2 µg) were denatured by incubation with 0.2 mol/liter NaOH for 10 min at 37 °C. Samples were treated with 3 M sodium bisulfite, 0.5 mmol/liter hydroquinone for 16 h at 50 °C. The bisulfite-treated DNA samples were purified with the DNA Wizard clean-up kit (Promega, Madison, WI) and desulfonated with 0.3 mol/liter NaOH followed by precipitation with ethanol and 6 mol/liter NH₄Ac using glycogen (20 µg) as a carrier. Precipitated bisulfite-treated DNA samples were resuspended in water and stored at –20 °C

Amplification of the H19 DMD and Sequencing—A region of the H19 DMD shown to be heavily methylated on the paternal allele and hypomethylated on the maternal allele in normal mouse liver (13) was amplified from bisulfite-treated DNA. This region is located between –1968 and –2555 relative to the transcriptional start site (based on accession number AF049091 [GenBank] ) and contains 26 CpG sites and one CTCF-binding site (14, 15). The reaction was performed using HotStar TaqDNA polymerase (Qiagen). The primers (H19DMD2, 5'ATGGTTCCCTTACACACTGAACCAGA-3', and H19DMD3, 5'CAGCCTCTGCTTTTATGGCTATGGGG-3') were designed such that only bisulfite-treated genomic DNA would amplify to produce a 588-bp band. Cycling conditions were 95 °C for 15 min followed by 35 cycles of 94 °C for 1 min, 50 °C for 1 min, and 72 °C for 1 min with a final extension of 10 min at 72 °C. PCR products were cloned into pCR-TOPO vector (Invitrogen), and plasmid DNA from the clones was purified using the Miniprep spin kit (Qiagen) followed by automated DNA sequencing using an Applied Biosystems model 3730 DNA analyzer (Foster City, CA) available through the DNA Core Facility of the University of Iowa. Twenty to forty clones containing the amplified H19 DMD PCR products were analyzed from brain, liver, and aorta from each animal.

Reverse Transcription of H19 and Igf2 Transcripts—Total RNA was extracted from liver, brain, and aorta using TRIzol reagent (Invitrogen). Samples were treated with DNase I (Promega), in the presence of RNase inhibitor (Promega), to remove contaminating genomic DNA. Integrity of the RNA was assessed by confirming the presence of 18 S and 28 S rRNA on agarose gels. For synthesis of cDNA, DNase I-treated RNA samples from liver (1.5 µg), brain (2.0 µg), or aorta (2.0 µg) were incubated with 1.25 units/µl Multiscribe reverse transcriptase (Applied Biosystems), 0.4 units/µl RNase inhibitor, 2.5 µmol/liter random hexamers, 500 µmol/liter each dNTPs, 5.5 mmol/liter MgCl₂, and TaqMan reverse transcription buffer in a final reaction volume of 80 µl. Samples were incubated at 25 °C for 10 min for annealing of random hexamers followed by incubation at 48 °C for 30 min for reverse transcription and 95 °C for 10 min for inactivation of reverse transcriptase.

Real-time PCR—Reverse-transcribed cDNA from liver (150 ng), brain (200 ng), or aorta (200 ng) was incubated with TaqMan Universal PCR mix (Applied Biosystems). For quantification of H19 transcripts, commercially designed PCR primers and TaqMan minor groove binder probes (FAM dye-labeled) specific for H19 (Mm00469706, Applied Biosystems) were used. For quantification of Igf2 transcripts, PCR primers and TaqMan minor groove binder probes (FAM dye-labeled) were designed by Applied Biosystems to amplify a region of the coding sequence of the Igf2 mRNA (accession number NM_010514 [GenBank] ). Samples were incubated at 50 °C for 2 min followed by incubation at 95 °C for 10 min and 40 cycles of 95 °C for 15 s and 60 °C for 1 min using the Applied Biosystems 7700 sequence detection system. Samples were run in triplicate. Amplicon-specific standard curves generated by serial dilution of cDNA were used to quantify the amount of H19 and Igf2 in each sample. For each unknown sample, cycle threshold values were determined, and the relative amount of cDNA was calculated using linear regression analysis from its respective standard curve. Data were analyzed using Sequence Detection software version 1.6.3 (Applied Biosystems). Levels of 18 S rRNA were determined using TaqMan ribosomal RNA control reagents (Applied Biosystems). Data for H19 and Igf2 are expressed as a ratio to levels of 18 S rRNA.

View larger version (17K): [in this window] [in a new window]   FIG. 2. Reduced methylation capacity in liver and brain of mice with hyperhomocysteinemia. A, concentrations of AdoMet (SAM) and AdoHcy (SAH) and AdoMet/AdoHcy (SAM/SAH) ratios in liver. Open bars, Cbs+/+ mice fed the control diet (n = 7); filled bars, Cbs+/– mice fed the HH diet (n = 15). B, concentrations of AdoMet and AdoHcy and AdoMet/AdoHcy ratios in brain. Open bars, Cbs+/+ mice fed the control diet (n = 7); filled bars, Cbs+/– mice fed the HH diet (n = 14). Values shown are means + S.E., *, p < 0.05, **, p < 0.001, as determined by one-way analysis of variance.

	RESULTS

TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 
Plasma tHcy and Methylation Capacity in Liver and Brain— Feeding the HH diet to Cbs+/– mice produced plasma tHcy levels of 94.7 ± 11.9 µmol/liter, almost 20-fold higher (p < 0.001) than the levels of 5.0 ± 0.3 µmol/liter in Cbs+/+ mice fed the control diet (Fig. 1). The elevation in plasma tHcy in the Cbs+/– mice fed the HH diet was accompanied by a reduction in tissue methylation capacity, with lower AdoMet/AdoHcy ratios (p < 0.001) in liver and brain when compared with Cbs+/+ mice fed the control diet (Fig. 2, A and B). These differences in methylation capacity were due primarily to higher levels of AdoHcy (p < 0.05) in the liver and brain of Cbs+/– mice fed the HH diet than Cbs+/+ mice fed the control diet. No significant differences in levels of AdoMet in liver or brain were observed between Cbs+/– mice fed the HH diet and Cbs+/+ mice fed the control diet. Overall, there was a negative correlation between plasma tHcy and AdoMet/AdoHcy ratios in liver (p < 0.01, r = 0.568) and brain (p < 0.05, r = 0.501).

Methylation of the H19 DMD—Methylation analysis of a region of the H19 DMD containing 26 CpGs was performed by bisulfite sequencing, a method in which incubation of DNA with sodium bisulfite converts all unmethylated cytosine residues to thymidine. Sequencing PCR products amplified from the H19 DMD of bisulfite-treated DNA indicated whether the cytosine residues at each of the 26 CpG sites were methylated (Fig. 3A). In the liver, the percentage of H19 DMD CpG sites that were methylated was less (p < 0.001) in Cbs+/– mice fed the HH diet than in Cbs+/+ mice fed the control diet (Fig. 3B). In Cbs+/– mice fed the HH diet, on average, 53.0 ± 0.7% of the CpGs (2757 of 5200 CpGs analyzed) were methylated when compared with 60.6 ± 0.6% (2615 of 4316 CpGs analyzed) in Cbs+/+ mice fed the control diet.

The converse effect on H19 DMD methylation was observed in the brain and aorta, where the percentage of CpG sites that were methylated was higher (p < 0.001) in Cbs+/– mice fed the HH diet than in Cbs+/+ mice fed the control diet (Fig. 3, C and D). The magnitude of the difference in H19 DMD methylation was highest in the brain, where an average of 70.5 ± 0.2% of the CpGs (2109 of 2990 CpGs analyzed) were methylated in Cbs+/– mice fed the HH diet when compared with 46.1 ± 0.3% (1355 of 2938 CpGs analyzed) in Cbs+/+ mice fed the control diet. In the aorta, an average of 77.8 ± 0.2% of the CpGs (2085 of 2678 CpGs analyzed) were methylated in Cbs+/– mice fed the HH diet when compared with 72.6 ± 0.4% (1869 of 2574 CpGs analyzed) in Cbs+/+ mice fed the control diet.

Levels of H19 and Igf2 Transcripts—To determine whether the changes in tissue methylation capacity and methylation profile of the H19 DMD in hyperhomocysteinemic mice were accompanied by tissue-specific alterations in the expression of H19 or Igf2, levels of H19 and Ifg2 transcripts were quantified by real-time PCR (Table II). In the liver and brain, levels of H19 transcripts did not differ significantly between Cbs+/+ mice fed the control diet and Cbs+/– mice fed the HH diet. In the aorta, higher levels of H19 transcripts (p = 0.02) were found in Cbs+/– mice fed the HH diet than in Cbs+/+ mice fed the control diet. Overall, there was a positive correlation (p < 0.05, r = 0.619) between levels of H19 transcripts in aorta and plasma tHcy concentration.

View larger version (30K): [in this window] [in a new window]   FIG. 3. Tissue-specific changes in the methylation status of the H19 DMD in mice with hyperhomocysteinemia. A, schematic representation of the 588-bp region of the H19 DMD analyzed by bisulfite sequencing. The region contains 26 CpG sites () and one CTCF-binding site (gray square) (14, 15). B, average percentage of methylation of the 26 CpG sites analyzed in liver from Cbs+/+ mice fed the control diet (•) (n = 5 animals) and Cbs+/– mice fed the HH diet () (n = 6 animals). C, average percentage of methylation of the 26 CpG sites in brain from Cbs+/+ mice fed the control diet (•)(n = 4 animals) and Cbs+/– mice fed the HH diet () (n = 4 animals). D, average percentage of methylation of the 26 CpG sites in aorta from Cbs+/+ mice fed the control diet (•) (n = 4 animals) and Cbs+/– mice fed the HH diet ()(n = 4 animals). For each animal, 25–40 PCR product clones were sequenced, and the average percentage of methylation of these clones was calculated. Results shown are the means + S.E. of the average percentage of methylation calculated for animals in each experimental group. *, p < 0.001, as determined by one-way analysis of variance.

Because H19 and Igf2 are reciprocally imprinted in the mouse, we compared the ratios of H19 transcripts with those of Igf2 transcripts in liver, brain, and aorta in each group of mice. The ratio of H19/Igf2 transcripts in liver and aorta did not differ significantly between Cbs+/+ mice fed the control diet and Cbs+/– mice fed the HH diet (Fig. 4, A and C). In the brain, which exhibited a large increase in H19 DMD methylation in Cbs+/– mice fed the HH diet when compared with Cbs+/+ mice fed the control diet (Fig. 3C), there was a corresponding decrease in the ratio of H19/Igf2 transcripts in Cbs+/– mice fed the HH diet (p = 0.006) (Fig. 4B).

	DISCUSSION

TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 
This work sought to determine whether the reduced methylation capacity in hyperhomocysteinemic mice is accompanied by hypomethylation of the H19 DMD and altered expression of H19 and Igf2 transcripts. We chose to study the effects of hyperhomocysteinemia in the liver because it is the primary site of homocysteine metabolism, and also in the aorta and brain, which are sites of pathology in humans with hyperhomocysteinemia (6).

There are three major findings of this study. First, we found that the effect of hyperhomocysteinemia on H19 DMD methylation is tissue-specific. In the liver, the reduced tissue methylation capacity (AdoMet/AdoHcy ratio) in Cbs+/– mice with hyperhomocysteinemia was accompanied by a significant decrease in methylation of the H19 DMD. In the brain, hyperhomocysteinemia also produced a decrease in the AdoMet/AdoHcy ratio, but the lower methylation capacity was paradoxically associated with an increase in methylation of the H19 DMD. Hyperhomocysteinemia in Cbs+/– mice was also associated with a significant increase in H19 DMD methylation in the aorta. The second major finding is that the reduced methylation capacity and increased H19 DMD methylation in the brain of mice with hyperhomocysteinemia was associated with a significant decrease in the ratio of H19/Igf2 transcripts, which suggests that DNA methylation plays a major role in regulating H19 and Igf2 expression in the brain. The third major finding is that hyperhomocysteinemia in Cbs+/– mice produced a 2.5-fold increase in the expression of H19 transcripts in aorta. This finding suggests a possible role for H19 transcripts in the vascular pathology associated with hyperhomocysteinemia.

View larger version (14K): [in this window] [in a new window]   FIG. 4. Tissue-specific changes in the ratio of H19/Igf2 transcript levels in mice with hyperhomocysteinemia. A, ratio of H19/Igf2 transcripts in liver from Cbs+/+ mice fed the control diet (n = 13) and Cbs+/– mice fed the HH diet (n = 13). B, ratio of H19/Igf2 transcripts in brain from Cbs+/+ mice fed the control diet (n = 11) and Cbs+/– mice fed the HH diet (n = 15). *, p < 0.01, as determined by one-way analysis of variance. C, ratio of H19/Igf2 transcripts in aorta from Cbs+/+ mice fed the control diet (n = 7) and Cbs+/– mice fed the HH diet (n = 7).

Interestingly, the increase in H19 DMD methylation in the brain was accompanied by a significant decrease in the ratio of H19 transcripts to Igf2 transcripts (Fig. 4B). This observation fits well with the boundary/insulator model of the H19 DMD in which CTCF binds to the unmethylated H19 DMD, allowing distal enhancers to activate H19 transcription whereas simultaneously inhibiting access of these enhancers to Igf2 (14–16). The mice with hyperhomocysteinemia did not, however, have an altered ratio of H19 transcripts to Igf2 transcripts in liver. This finding suggests that control of H19 and Igf2 expression in liver involves other regulatory factors besides H19 DMD methylation.

We also found a significant increase in the levels of H19 transcripts in aorta from Cbs+/– mice fed the HH diet. The increased expression of H19 transcripts was likely unrelated to the methylation status of the H19 DMD because these mice had a modest increase in methylation of the H19 DMD in aorta. The effect of hyperhomocysteinemia on levels of H19 transcripts in aorta may be a consequence of homocysteine-related changes in the expression and/or ability of CTCF to bind to the H19 DMD, changes in the methylation status of other sites within the imprinting control region, or an effect on some other yet uncharacterized factor required for H19 transcription.

The finding of increased levels of H19 transcripts in aorta of Cbs+/– mice fed the HH diet may have implications for the vascular pathology of hyperhomocysteinemia. H19 belongs to a family of imprinted genes that encode untranslated RNA transcripts. Some studies suggest that H19 mRNA may function as a tumor suppressor, whereas others have shown increased expression of H19 in tumors (29, 30). Increased expression of H19 transcripts has been demonstrated in rat carotid arteries following balloon injury (18) and in human atherosclerotic plaques (19). Overexpression of H19 in a bladder carcinoma cell line was associated with increased expression of tumor necrosis factor-, a factor implicated in the vascular pathology associated with hyperhomocysteinemia (31, 32).

In summary, this study demonstrated that Cbs+/– mice with hyperhomocysteinemia have reduced tissue methylation capacity accompanied by tissue-specific changes in the methylation and expression of H19. In this model, changes in methylation of the H19 DMD did not strictly correlate with changes in the expression of H19 or Igf2 transcripts. These findings suggest that other factors besides H19 DMD methylation contribute to the regulation of H19 and Igf2 expression in hyperhomocysteinemia. The tightest correlation between H19 DMD methylation and regulation of H19 and Igf2 expression was seen in the brain, which suggests that H19 DMD methylation is a stronger regulator of H19 expression in the brain. Despite the variable relationship between H19 DMD methylation and H19 expression in different tissues, it is clear that hyperhomocysteinemia can have profound effects on the methylation and expression of imprinted genes in adult animals. Additional work will be required to define the exact mechanism(s) by which homocysteine affects expression of H19 and the role of H19 in the vascular pathology of hyperhomocysteinemia.

	FOOTNOTES

 
^* This work was supported by the Office of Research and Development, United States Department of Veterans Affairs, National Institutes of Health Grants HL63943 and NS24621, and American Heart Association Beginning Grant-in-aid 0465315Z (to A. M. D.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Present address: Nutrition Research Program, University of British Columbia, BC Research Institute for Children's and Women's Health, 950 West 28th Ave., Vancouver, Canada.

To whom correspondence should be addressed: Dept. of Internal Medicine, C32 GH, The University of Iowa, IA 52242. Tel.: 319-356-4048; Fax: 319-335-8848; E-mail: steven-lentz{at}uiowa.edu.

¹ The abbreviations used are: tHcy, total homocysteine; AdoHcy, S-adenosylhomocysteine; AdoMet, S-adenosylmethionine; Cbs, cystathionine--synthase; CpG, CG dinucleotide; CTCF, CCCTC-binding factor; DMD, differentially methylated domain; HH, hyperhomocysteinemic diet; IGF2, insulin-like growth factor 2; HPLC, high performance liquid chromatography.

	ACKNOWLEDGMENTS

 
We thank Dr. Sanjana Dayal, Ryan McCaw, and Sara Rozen for technical assistance.

	REFERENCES

TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 

1. Herman, J. G., and Baylin, S. B. (2003) N. Engl. J. Med. 349,2042 –2054[Free Full Text]
2. Laukkanen, M. O., Mannermaa, S., Hiltunen, M. O., Aittomaki, S., Airenne, K., Janne, J., and Yla-Herttuala, S. (1999) Arterioscler. Thromb. Vasc. Biol. 19,2171 –2178[Abstract/Free Full Text]
3. Hiltunen, M. O., Turunen, M. P., Hakkinen, T. P., Rutanen, J., Hedman, M., Makinen, K., Turunen, A. M., alto-Setala, K., and Yla-Herttuala, S. (2002) Vasc. Med. 7,5 –11[Abstract/Free Full Text]
4. Lund, G., Andersson, L., Lauria, M., Lindholm, M., Fraga, M. F., Villar-Garea, A., Ballestar, E., Esteller, M., and Zaina, S. (2004) J. Biol. Chem. 279,29147 –29154[Abstract/Free Full Text]
5. Post, W. S., Goldschmidt-Clermont, P. J., Wilhide, C. C., Heldman, A. W., Sussman, M. S., Ouyang, P., Milliken, E. E., and Issa, J. P. (1999) Cardiovasc. Res. 43,985 –991[Abstract/Free Full Text]
6. Homocysteine Studies Collaboration (2002) J. Am. Med. Assoc. 288,2015 –2022[Abstract/Free Full Text]
7. Finkelstein, J. D. (1990) J. Nutr. Biochem. 1,228 –237[CrossRef][Medline] [Order article via Infotrieve]
8. Yi, P., Melnyk, S., Pogribna, M., Pogribny, I. P., Hine, R. J., and James, S. J. (2000) J. Biol. Chem. 275,29318 –29323[Abstract/Free Full Text]
9. Castro, R., Rivera, I., Struys, E. A., Jansen, E. E., Ravasco, P., Camilo, M. E., Blom, H. J., Jakobs, C., and Tavares de Almeida, I. (2003) Clin. Chem. 49,1292 –1296[Abstract/Free Full Text]
10. Chen, Z., Karaplis, A. C., Ackerman, S. L., Pogribny, I. P., Melnyk, S., Lussier-Cacan, S., Chen, M. F., Pai, A., John, S. W. M., Smith, R. S., Bottiglieri, T., Bagley, P., Selhub, J., Rudnicki, M. A., James, S. J., and Rozen, R. (2001) Hum. Mol. Genet. 10,433 –443[Abstract/Free Full Text]
11. Dayal, S., Bottiglieri, T., Arning, E., Maeda, N., Malinow, M. R., Sigmund, C. D., Heistad, D. D., Faraci, F. M., and Lentz, S. R. (2001) Circ. Res. 88,1203 –1209[Abstract/Free Full Text]
12. Devlin, A. M., Arning, E., Bottiglieri, T., Faraci, F. M., Rozen, R., and Lentz, S. R. (2004) Blood 103,2624 –2629[Abstract/Free Full Text]
13. Thorvaldsen, J. L., Duran, K. L., and Bartolomei, M. S. (1998) Genes Dev. 12,3693 –3702[Abstract/Free Full Text]
14. Bell, A. C., and Felsenfeld, G. (2000) Nature 405,482 –485[CrossRef][Medline] [Order article via Infotrieve]
15. Hark, A. T., Schoenherr, C. J., Katz, D. J., Ingram, R. S., Levorse, J. M., and Tilghman, S. M. (2000) Nature 405,486 –489[CrossRef][Medline] [Order article via Infotrieve]
16. Kaffer, C. R., Srivastava, M., Park, K. Y., Ives, E., Hsieh, S., Batlle, J., Grinberg, A., Huang, S. P., and Pfeifer, K. (2000) Genes Dev. 14,1908 –1919[Abstract/Free Full Text]
17. Ingrosso, D., Cimmino, A., Perna, A. F., Masella, L., De Santo, N. G., De Bonis, M. L., Vacca, M., D'Esposito, M., D'Urso, M., Galletti, P., and Zappia, V. (2003) Lancet 361,1693 –1699[CrossRef][Medline] [Order article via Infotrieve]
18. Kim, D. K., Zhang, L., Dzau, V. J., and Pratt, R. E. (1994) J. Clin. Investig. 93,355 –360
19. Han, D. K., Khaing, Z. Z., Pollock, R. A., Haudenschild, C. C., and Liau, G. (1996) J. Clin. Investig. 97,1276 –1285[Medline] [Order article via Infotrieve]
20. Zaina, S., Pettersson, L., Ahren, B., Branen, L., Hassan, A. B., Lindholm, M., Mattsson, R., Thyberg, J., and Nilsson, J. (2002) J. Biol. Chem. 277,4505 –4511[Abstract/Free Full Text]
21. Eberhardt, R. T., Forgione, M. A., Cap, A., Leopold, J. A., Rudd, M. A., Tolliet, M., Heyrick, S., Stark, R., Klings, E. S., Moldovan, N. I., Yaghoubi, M., Goldschmidt-Clermont, P. J., Farber, H. W., Cohen, R., and Loscalzo, J. (2000) J. Clin. Investig. 106,483 –491[Medline] [Order article via Infotrieve]
22. Dayal, S., Arning, E., Bottiglieri, T., Böger, R. H., Sigmund, C. D., Faraci, F. M., and Lentz, S. R. (2004) Stroke 35,1957 –1962[Abstract/Free Full Text]
23. Watanabe, M., Osada, J., Aratani, Y., Kluckman, K., Reddick, R., Malinow, M. R., and Maeda, N. (1995) Proc. Natl. Acad. Sci. U. S. A. 92,1585 –1589[Abstract/Free Full Text]
24. Mudd, S. H., Finkelstein, J. D., Refsum, H., Ueland, P. M., Malinow, M. R., Lentz, S. R., Jacobsen, D. W., Brattström, L., Wilcken, B., Wilcken, D. E. L., Blom, H. J., Stabler, S. P., Allen, R. H., Selhub, J., and Rosenberg, I. H. (2000) Arterioscler. Thromb. Vasc. Biol. 20,1704 –1706[Free Full Text]
25. Martin, S. C., Hilton, A. C., Bartlett, W. A., and Jones, A. F. (1999) Biomed. Chromatogr. 13,81 –82[CrossRef][Medline] [Order article via Infotrieve]
26. Bottiglieri, T. (1990) Biomed. Chromatogr. 4,239 –241[CrossRef][Medline] [Order article via Infotrieve]
27. Frommer, M., McDonald, L. E., Millar, D. S., Collis, C. M., Watt, F., Grigg, G. W., Molloy, P. L., and Paul, C. L. (1992) Proc. Natl. Acad. Sci. U. S. A. 89,1827 –1831[Abstract/Free Full Text]
28. Yap, S., Naughten, E. R., Wilcken, B., Wilcken, D. E., and Boers, G. H. (2000) Semin. Thromb. Hemostasis 26,335 –340[CrossRef][Medline] [Order article via Infotrieve]
29. Hao, Y., Crenshaw, T., Moulton, T., Newcomb, E., and Tycko, B. (1993) Nature 365,764 –767[CrossRef][Medline] [Order article via Infotrieve]
30. Ariel, I., Miao, H. Q., Ji, X. R., Schneider, T., Roll, D., de, G. N., Hochberg, A., and Ayesh, S. (1998) Mol. Pathol. 51,21 –25[Abstract]
31. Ayesh, S., Matouk, I., Schneider, T., Ohana, P., Laster, M., Al-Sharef, W., de-Groot, N., and Hochberg, A. (2002) Mol. Carcinog. 35,63 –74[CrossRef][Medline] [Order article via Infotrieve]
32. Ungvari, Z., Csiszar, A., Edwards, J. G., Kaminski, P. M., Wolin, M. S., Kaley, G., and Koller, A. (2003) Arterioscler. Thromb. Vasc. Biol. 23,418 –424[Abstract/Free Full Text]

CiteULike

Complore

Connotea

Del.icio.us

Digg

Reddit

Technorati

This article has been cited by other articles:

				P.-Y. Chang, S.-C. Lu, C.-M. Lee, Y.-J. Chen, T. A. Dugan, W.-H. Huang, S.-F. Chang, W. S.L. Liao, C.-H. Chen, and Y.-T. Lee Homocysteine Inhibits Arterial Endothelial Cell Growth Through Transcriptional Downregulation of Fibroblast Growth Factor-2 Involving G Protein and DNA Methylation Circ. Res., April 25, 2008; 102(8): 933 - 941. [Abstract] [Full Text] [PDF]

				A D. Smith, Y.-I. Kim, and H. Refsum Is folic acid good for everyone? Am. J. Clinical Nutrition, March 1, 2008; 87(3): 517 - 533. [Abstract] [Full Text] [PDF]

				A. M. Devlin, R. Singh, R. E. Wade, S. M. Innis, T. Bottiglieri, and S. R. Lentz Hypermethylation of Fads2 and Altered Hepatic Fatty Acid and Phospholipid Metabolism in Mice with Hyperhomocysteinemia J. Biol. Chem., December 21, 2007; 282(51): 37082 - 37090. [Abstract] [Full Text] [PDF]

				E. Sontag, V. Nunbhakdi-Craig, J.-M. Sontag, R. Diaz-Arrastia, E. Ogris, S. Dayal, S. R. Lentz, E. Arning, and T. Bottiglieri Protein Phosphatase 2A Methyltransferase Links Homocysteine Metabolism with Tau and Amyloid Precursor Protein Regulation J. Neurosci., March 14, 2007; 27(11): 2751 - 2759. [Abstract] [Full Text] [PDF]

				S. Dayal, K. M. Wilson, L. Leo, E. Arning, T. Bottiglieri, and S. R. Lentz Enhanced susceptibility to arterial thrombosis in a murine model of hyperhomocysteinemia Blood, October 1, 2006; 108(7): 2237 - 2243. [Abstract] [Full Text] [PDF]

				A. M. Devlin and S. R. Lentz ApoA-I: A Missing Link Between Homocysteine and Lipid Metabolism? Circ. Res., March 3, 2006; 98(4): 431 - 433. [Full Text] [PDF]

This Article Abstract Full Text (PDF) All Versions of this Article: 280/27/25506    most recent M504815200v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Devlin, A. M. Articles by Lentz, S. R. Search for Related Content PubMed PubMed Citation Articles by Devlin, A. M. Articles by Lentz, S. R. Social Bookmarking                      What's this?